Modified and derivatized ß-glucan compounds, compositions, and methods
AssigneeBiothera, Inc.
InventorsNandita Bose, William J. Grossman, Michael Danielson, Andrew Magee, Paul Will, Kyle S. Michel, Vanessa A. Iiams, Xiaohong Qiu, Mary Antonysamy
Life of this patent
Estimating the term…
Abstract
Modified and/or derivativized β-glucans with an enhanced capacity to modulate human immune response as compared to the parent, unmodified and/or underivatized β-glucans are demonstrated.
Claims20
1-41. (canceled)
A composition comprising a chemically modified beta 1,3 linked glucose polymer of at least 3 glucose residues having a backbone with at least one glucose residue linked to the backbone via a beta 1,6 linkage resulting in a sidechain, wherein at least one glucose residue containing a vicinal diol within the polymer has been transformed into a substituted morpholine or [1,4]-oxazepane via periodate oxidation and reductive amination with a protein.
A composition comprising a chemically modified beta 1,3 linked glucose polymer of at least 3 glucose residues having at least one hydroxyl group of the polymer linked to a second amine via an imidocarbamate linkage formed via cyanogen bromide or 1-cyano-4-dimethylaminopyridinium tetrafluoroborate.
A composition comprising a chemically modified beta 1,3 linked glucose polymer of at least 3 glucose residues wherein at least one hydroxyl group of the polymer is alkylated with a HBr salt of 1-amino-3-bromopropane resulting in a primary propyl amine.
A composition comprising a chemically modified beta 1,3 linked glucose polymer of at least 3 glucose residues in which at least one primary hydroxyl group of the polymer is oxidized to a carboxylic acid.
Dependencies are inferred from the claim text.